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Endothelin-1 Immunoreactivity and its Association with
Intramedullary Hemorrhage and Myelomalacia in Naturally
Occurring Disk Extrusion in Dogs
D. Mayer, A. Oevermann, T. Seuberlich, M. Vandevelde, A. Casanova-Nakayama, S. Selimovic-Hamza,
F. Forterre, and D. Henke
Background: The pathophysiology of ascending/descending myelomalacia (ADMM) after canine intervertebral disk (IVD)
extrusion remains poorly understood. Vasoactive molecules might contribute.
Hypothesis/Objectives: To investigate the immunoreactivity of endothelin-1 (ET-1) in the uninjured and injured spinal
cord of dogs and its potential association with intramedullary hemorrhage and extension of myelomalacia.
Animals: Eleven normal control and 34 dogs with thoracolumbar IVD extrusion.
Methods: Spinal cord tissue of dogs retrospectively selected from our histopathologic database was examined histologi-
cally at the level of the extrusion (center) and in segments remote from the center. Endothelin-1 immunoreactivity was exam-
ined immunohistochemically and by in situ hybridization. Associations between the immunoreactivity for ET-1 and the
severity of intramedullary hemorrhage or the extension of myelomalacia were examined.
Results: Endothelin-1 was expressed by astrocytes, macrophages, and neurons and only rarely by endothelial cells in all
dogs. At the center, ET-1 immunoreactivity was significantly higher in astrocytes (median score 4.02) and lower in neurons
(3.21) than in control dogs (3.0 and 4.54) (P < .001; P = .004) irrespective of the grade of hemorrhage or myelomalacia. In
both astrocytes and neurons, there was a higher ET-1 immunoreactivity in spinal cord regions remote from the center (4.58
and 4.15) than in the center itself (P = .013; P = .001). ET-1 mRNA was present in nearly all neurons with variable inten-
sity, but not in astrocytes.
Conclusion and Clinical Importance: Enhanced ET-1 immunoreactivity over multiple spinal cord segments after IVD
extrusion might play a role in the pathogenesis of ADMM. More eﬀective quantitative techniques are required.
Key words: Dog; Intramedullary hemorrhage; IVD extrusion; Myelomalacia.
Spinal cord injury (SCI) after intervertebral disk(IVD) extrusion is a common disease in dogs and
leads to tissue damage ranging from mild changes of
gray and white matter to significant structural destruc-
tion and softening of the spinal cord tissue, the so-
called myelomalacia.1,2 Myelomalacia can remain focal
at the IVD extrusion site or might ascend, descend, or
both into adjacent spinal cord segments or even the
whole spinal cord.3–5
After the primary mechanical insult, secondary mecha-
nisms including decreased vascular perfusion followed by
ischemia and perivascular edema, electrolyte imbalances,
glutamatergic excitotoxicity, oxidative stress, inflamma-
tion, and apoptosis lead to further damage of the spinal
cord parenchyma.6,7 Additionally, in connection with
hemorrhage resulting from primary or secondary spinal
cord injury, vasoactive molecules contribute to further
disruption of the blood spinal cord barrier (BSCB).8
Several underlying molecular mechanisms have been
investigated in this respect experimentally such as overex-
pression of the Sur1-Trpm4 channel9–11 and of endothe-
lin-1 (ET-1).12
Among the three ET isoforms, ET-1 is the most
abundant and physiologically relevant form, and is
expressed in liver, lung, kidneys, brain and spinal cord
and binds to either the ETA or ETB receptor.
13–16 It is a
potent vasoconstrictor.17,18 The vasoactive function of
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Abbreviations:
IVD intervertebral disk
ET-1 endothelin-1
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ADMM ascending/descending myelomalacia
BSCB blood spinal cord barrier
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IHC immunohistochemistry
DEPC diethylpyrocarbonate
PBS phosphate-buﬀered saline
RT room temperature
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ET-1 is mediated by G protein-coupled endothelin
receptors, ETA and ETB2, in smooth muscle cells of
blood vessels,18 and is thought to lead to vasospasm
resulting in ischemic damage to neurons.8,19,20 On the
other hand, binding of ET-1 to the ETB1 receptor on
endothelial cells leads to vasodilatation via generation
of NO.18Additionally, the ETB receptor has been shown
to be expressed on radial glia cells, ependymal cells,
vascular endothelial cells, and astrocytes in rodents.16
ET-1 regulates several astroglial functions among others
mitogenesis, intracellular Ca2+ levels, glutamate eﬄux,
and synthesis of inflammatory mediators.21–24
The formation of ET-1 is stimulated by oxyhe-
moglobin either derived from the injured tissue itself, or
from red blood cells after disruption of blood vessels a
frequent complication of SCI.12,20,25 In experimental
SCI in rats, ET-1 synthesis is initially upregulated in
neurons and endothelial cells26,27 and delayed in reac-
tive astrocytes.24,28
The pathophysiology of ascending/descending myelo-
malacia (ADMM) after IVD extrusion remains poorly
understood. Even though intramedullary hemorrhage is
a very common finding5,29,30 and is associated with the
severity of spinal cord damage in the center and the
longitudinal extension of myelomalacia,5 the precise
mechanism how hemorrhage could induce progressive
extension of myelomalacia in dogs after IVD extrusion
remains unknown. Since oxyhemoglobin stimulates the
expression of ET-1, a potent vasoconstrictor and regula-
tor of astrocytic functions, we hypothesize that intrame-
dullary hemorrhage upregulates the expression of ET-1
which could be detrimental to the spinal cord parench-
yma leading to further extension of myelomalacia.
Therefore, the purpose of the present study was to
investigate the immunoreactivity of ET-1 in the unin-
jured and injured canine spinal cord and its potential
association with intramedullary hemorrhage and sever-
ity of myelomalacia with special emphasis on ADMM,
by semiquantitative immunohistochemistry (IHC) and
in situ hybridization (ISH).
Materials and Methods
Histopathologic examination of the spinal cord was performed
in 34 dogs with thoracolumbar IVD extrusion which were eutha-
nized between January 1991 and December 2014 at the veterinary
teaching hospital of the University of Bern. Inclusion criteria were
well-documented records of the neurologic history, and availability
of histologic sections of the entire spinal cord.
Additionally, 11 dogs without clinical signs of a spinal cord
pathologies and histologic changes, which had been euthanized
because of other pathologies, were included as controls.
Clinical Data
Data collected from the medical records included breed, age,
sex, duration and severity of clinical signs, and treatment.
Duration of neurologic signs was defined as the time between
the first observed clinical signs and euthanasia, and was catego-
rized as follows: euthanasia within the first 24 hours after onset of
signs (acute), between 25 hours and 7 days after onset (subacute),
or after more than 7 days (chronic) according to previous
studies.31
A complete neurologic examination was performed maximally
12 hours before euthanasia. Neurological condition was graded on
a I–V scale as published before31; grade I: spinal hyperesthesia
only; grade II: ambulatory paraparesis and ataxia or ataxia, and
proprioceptive or proprioceptive; deficits, grade III: nonambula-
tory paraparesis; grade IV: paraplegia with present nociception;
grade V: paraplegia with loss of nociception.
Histopathologic Examination
The processing of the material followed the same established
standardized protocol in all dogs.
The spinal cord was removed within 12 hours after euthanasia
in all aﬀected as well as control dogs (ranging from 2 hours to
12 hours), and then fixed in 10% formalin. For gross inspection,
the fixed spinal cord was cross-sectioned at multiple levels; namely
at the site of the IVD extrusion (“center”), the immediately adja-
cent segments on either side of the center, additional segments of
the spinal cord exhibiting macroscopic changes, and finally more
remote proximal and distal segments without grossly visible lesions
including the upper cervical spinal cord, cervical intumescence,
and lumbar intumescence. In control dogs, the spinal cord was
cross-sectioned at diﬀerent levels including the upper cervical
spinal cord, cervical intumescence, thoracolumbar spinal cord and
lumbar intumescence. Cross-sectioned blocks of these levels were
embedded in paraﬃn wax within 14 days, after a standard proto-
col, and sections of 5 lm were cut from all samples and stained
with hematoxylin and eosin for histopathologic assessment. The
number of transverse sections cut and stained ranged from 10 to
30 and depended on the longitudinal extension of the lesion.
Semiquantitative Assessment of Spinal Cord Damage
and Hemorrhage
All slides were examined and graded independently by two
experienced observers (DH, MV). If discordance occurred between
the observers, slides were re-examined and consensus was agreed.
To evaluate the longitudinal extension of the lesion, the pres-
ence of myelomalacia, defined as complete loss of structural integ-
rity of spinal cord parenchyma, was assessed on all sections of
each animal, thus including the center, adjacent and more remote
spinal cord segments. The longitudinal extension was categorized
as grade 0 (no malacia), grade 1 (focal malacia at the center), and
grade 2 (ADMM from the center across at least 3 spinal cord seg-
ments) as previously described and illustrated.5
Intramedullary hemorrhage was categorized as grade 0 (no
hemorrhage), grade 1 (scattered ring hemorrhages), grade 2 (coa-
lescing ring hemorrhages and diﬀuse spread of erythrocytes in the
parenchyma), or grade 3 (mass hemorrhage) as previously
described and illustrated.5
Immunohistochemistry
Paraﬃn-embedded spinal cord sections were immunostained for
ET-1. Native slides were deparaﬃnized using xylene, rehydrated in
graded ethanol, pretreated with heat-induced antigen retrieval in
citrate buﬀer (pH = 6) at 95°C for 20 minutes using a laboratory
microwave. Sections were blocked with 10% normal goat serum
for 2 hours at room temperature (RT), and then incubated with
antibodies against ET-1 (monoclonal mouse; 1 : 350 dilution;
Abcam; the antibody had been predicted by the provider to bind
to canine ET-1) for 12 hours at 4°C. Subsequently, endogenous
peroxidase was blocked with 3% H2O2 in methanol over 15 min-
utes at RT. Then, slides were incubated with biotinylated goat
anti-mouse IgG (1 : 1000, Milan Analytica) for 1 hour, and there-
after with peroxidase-streptavidin (1 : 1000, Milan Analytica) for
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30 minutes at RT. Immunohistochemical staining was visualized
by incubating the slides with 3-amino-9-ethylcarbazole for
6–8 minutes at RT, and by counterstaining with Mayer’s hema-
toxylin. Sections from canine liver tissue treated in the same way
served as positive controls. Negative controls were performed
using nonspecific mouse IgG instead of the primary antibody in
the same concentration on both canine liver tissue and on spinal
cord sections.
Qualitative and Semiquantitative Assessment of
Immunohistochemistry
Immunohistochemical staining of blinded spinal cord sections
from dogs with IVD extrusion and control dogs was evaluated
and graded by 2 observers (DM, DH) independently. In cases of
disagreement between them, the slides were re-evaluated and con-
sensus was agreed.
Every animal was evaluated at two spinal cord levels, including
a cross-section of the cord at the level of the IVD extrusion, either
in the center or in a directly adjacent segment if the former was
completely necrotic. In addition, a cross-section of the cord remote
from the IVD extrusion site was examined: the section with the
lowest level of histopathological parenchymal damage of all avail-
able spinal cord sections was selected.
Positively stained astrocytes were identified according to their
large cytoplasm, clear nucleus, and star-shaped cell processes. The
number of positively stained astrocytes in the white matter of the
selected cord sections was counted in three diﬀerent randomized
visual fields at 409 magnification, and then summated and catego-
rized into four grades: grade 1 (≤20 positively stained astrocytes
per visual field), grade 2 (21–40), grade 3 (41–60), and grade 4
(61–80). In case of severe tissue destruction in the center, the clos-
est adjacent segment revealing preserved white matter parenchyma
in at least 3 visual fields (without malacia) was used.
The percentage of positively stained large neurons in the gray
matter of the ventral horns and intermedio-lateral horns was
categorized in 3 grades: grade 1 (<50% of the neurons positively
stained), grade 2 (50–75%), and grade 3 (>75%).
The intensity of the IHC staining of the diﬀerent cell types was
judged against defined standard sections and assessed as grade 0
(no staining), grade 1 (mild), grade 2 (moderate), and grade 3
(strong) (Fig 1).
Finally, the ET-1 immunoreactivity of astrocytes was demon-
strated as a score after summation of number and intensity grades
(ET-1 immunoreactivity score astrocytes = grade “number of posi-
tively stained astrocytes” + grade “intensity of astrocytic staining”).
The same was calculated for the ET-1 immunoreactivity of neurons.
Statistical Analyses
The after associations were statistically evaluated using a Krus-
kal-Wallis test on Ranks test with Bonferroni correction for multi-
ple comparisons: the association between ET-1 immunoreactivity
(in both the center and remote from the center) and (1) grade of
intramedullary hemorrhage, (2) degree of longitudinal extension of
myelomalacia as evaluated on sequential sections, and (3) duration
of clinical signs. In addition, ET-1 immunoreactivity at the level of
the IVD extrusion was compared to the ET-1 immunoreactivity in
spinal cord segments remote from the IVD extrusion site.
For statistical analyses, hemorrhage grades of 0 and 1; neuronal
ET-1 immunoreactivity grade of 1 and 2, and of grade 5 and 6;
and astrocytic ET-1 immunoreactivity grade of 2 and 3, and of
grade 6 and 7 were grouped together because of the small sample
numbers (Table S1). The threshold for statistical significance was
set to P < .05. All statistical analyses were performed using a sta-
tistical software package (NCSS 2009, www.ncss.com).
Probe Production for In Situ Hybridization
For generating a RNA probe to detect mRNA of ET-1 in for-
malin-fixed paraﬃn-embedded tissues of dogs, a 400 bp DNA
fragment of the ET-1 gene was synthesized (Eurofins, Germany).
A B
C D
Fig 1. Spinal cord cross-sections showing diﬀerent intensities of immunohistochemical staining for endothelin-1 in neurons. Standard sec-
tions of diﬀerent staining intensities of neurons (arrows) are presented: A- Grade 0: no positive staining, B- Grade 1: mild positive staining,
C- Grade 2: moderate positive staining, and D- Grade 3: strong positive staining, note the distinct granular cytoplasmatic staining. (IHC,
bar = 50 lm)
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This fragment corresponded to the sequence of nucleotides 481–
880 of the canine mRNA for preproendothelin-1 available in the
NCBI gene bank (access number: AB115087.1). The fragment con-
tained additional 50 and 30 sequences for the restriction enzymes
BamHI (GGATCC) and EcoRI (GAATTC), respectively, and was
cloned into the pSPT18 plasmid (Roche). The resulting plasmid
pSPT-18_ET-1 was transfected into bacteria (XL10-Gold Ultra-
competent Cells, Agilent). The inserted sequence was confirmed by
PCR-screening and DNA sequencing.
For in-vitro transcription of digoxigenin (DIG)-labeled RNA,
pSPT-18_ET-1 was linearized with BamHI for the antisense probe
or EcoRI for the sense probe, respectively.
The RNAs were transcribed from the linearized plasmids with
the DIG-RNA Labeling Kit (Roche Applied Science) according to
the manufacturer’s recommendations. In order to remove remain-
ing DNA, the reactions were treated with DNase I (15 minutes,
37°C) and purified by ethanol precipitation. T7 RNA polymerase
served to transcribe the antisense probe and SP6 RNA polymerase
the sense probe.32,33 Agarose gel electrophoresis was used to esti-
mate the amount of probes for in situ hybridization. The probes
were stored at !20°C.
In Situ Hybridization
Liver and selected spinal cord sections were deparaﬃnized with
xylene and rehydrated through graded ethanol. Afterward, slides
were incubated in diethylpyrocarbonate (DEPC) water (5 minutes,
RT), phosphate-buﬀered saline (PBS) (5 minutes, RT), and 0.2M
HCl for denaturation (20 minutes, RT). Between all steps sections
were rinsed with 29 SSC (sodium chloride/sodium citrate buﬀer)
in DEPC water. Slides were then treated with proteinase K (1.12–
1.76 lg/mL) solution (15 minutes, 37°C) and proteinase activity
was blocked by 0.2% glycine in PBS (2 minutes, RT). Addition-
ally, slides were incubated in 4% paraformaldehyde to denature
proteinase K and to refixate the tissue (5 minutes, RT).
A pretreatment with acetic anhydride (0.25%) in triethanolamine
was used to reduce the background staining and to inactivate RNases
(15 minutes, 37°C). Sections were then incubated in prehybridization
solution (49 SSC, 50% formamide, 29 Denhardt’s, 10 mg/mL yeast
RNA) (2 hour, 50°C). The slides were incubated overnight with
probes (final concentration: 50.9–80.0 lg/mL) in hybridization buﬀer
(49 SSC, 50% formamide, 29 Denhardt’s, 10 mg/mL yeast RNA,
10% dextran sulfate) covered with GelBonds at 50°C in a humidified
box. Slides were then treated with RNase (200 U/mL RNase T1 and
0.2 lg/mL RNase DNase-free, Roche) at 37°C for 30 minutes and
washed with 29 SSC and 0.29 SSC (10 minutes, 55°C). First 10%
blocking buﬀer (Roche) and afterward BSA-TritonX-100 solution
(0.1 mM Tris-HCl and 0.15 M NaCl with 1% BSA and 0.3% Tri-
tonX-100) were used for blocking. Anti-DIG-antibodies conjugated
with alkaline phosphatase (1 : 3000, Roche) in BSA-TritonX-100
were used to detect DIG-labeled RNA probes. After washing the sec-
tions with BSA-TritonX-100 solution and a buﬀer (10 mM Tris,
10 mMNaCl and 50 mMMgCl2*6H2O; pH = 9.5), slides were incu-
bated with NBT/BCIP (5-bromo-4-chloro-3-indolyl phosphate and
nitro blue tetrazolium) overnight in the dark covered with GelBonds.
The reaction was stopped with 0.01 M TrisHCl and 1 mM EDTA
(10 minutes, RT, dark).
The type of positively stained cells was determined according to
their phenotype.
Results
Clinical data
Thirty-four dogs met the inclusion criteria. In all of
these dogs, histologic examination and IHC for ET-1
was done. Spinal cords of 25 of these 34 dogs were
additionally analyzed by ISH. These breeds were
included; Aﬀected group: 7 French bulldog, 4 mixed-
breed dogs, 3 German Shepherd dogs, 2 Border collie, 2
Dachshund, 2 Lhasa Apso, and 1 each of Alaskan
Malamute, Beagle, Cavalier King Charles spaniel, Chin
chinois, Cocker spaniel, Coton de Tulear, German spa-
niel, Jack Russel Terrier, Labrador retriever, Mallinois,
Pekingese, Shih Tzu, Tibet Terrier, and Yorkshire
Terrier.
Ages of the diseased dogs ranged from 3 to 14 years
(mean 6.4 years). Eighteen dogs were male intact, 3
male castrated, 8 female intact, and 5 female spayed.
The mean duration of clinical signs was 10 days
(range 1–90 days), and the clinical signs were classified
as acute in 5 dogs, subacute in 17 dogs, and chronic in
12 dogs accordingly.
Fifteen dogs were euthanized at the request of the
owners because of initial poor prognosis. Fifteen dogs
received decompressive surgery (hemilaminectomy) and
4 dogs were treated conservatively. These dogs were
euthanized because of lack of improvement or deterio-
ration of clinical signs.
The neurological status before euthanasia was grade
II in 1, grade III in 3, grade IV in 6, and grade V in 24
dogs. Four dogs of the latter group developed clinical
signs of ADMM (involvement of thoracic limbs,
reduced segmental spinal reflexes of pelvic limbs)
(Table 1).
Additionally, 11 control dogs of diﬀerent breeds were
included: 2 Golden Retrievers, 2 mixed-breed dogs, and
1 each of Bernese mountain dog, Bichon frise, Dachs-
hund, French bulldog, Lhasa apso, Pug dog, and
Samojede.
Ages ranged from 1 month to 11 years (mean
5.3 years). Seven dogs were male intact and 4 female
intact.
Histopathological Findings
All dogs exhibited spinal cord lesions at the center
with varying degrees of edema of the parenchyma, axo-
nal swelling, neuronal necrosis, invasion of neutrophils,
and macrophages. In cases with severe tissue destruc-
tion in the center, the spinal cord tissue was replaced by
an amorphous mixture of spinal cord tissue debris,
macrophages, and blood. In those dogs, this hemor-
rhagic necrotic material was also found inside or dorsal
to the central canal, or both in spinal cord segments
distant from the center of the lesion in otherwise mildly
damaged spinal cord tissue as described previously.5
Gliosis and vascular proliferation were present in
chronic cases. The severity of the spinal cord lesions
generally correlated well with the neurological grades at
the time of euthanasia as reported before.2
In all but 9 dogs, areas of myelomalacia (complete
lysis of spinal cord tissue) of varying size were seen on
cross-sections (Fig 2A1). On longitudinal assessment,
myelomalacia extended from the center into the neigh-
boring segments in many animals. Accordingly, the
grade of myelomalacia was classified as focal
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myelomalacia in 11 dogs, and extended over more than
3 segments of the spinal cord (ADMM) in 14 dogs
(Table 1).
Intramedullary hemorrhage was frequently observed
with the largest extent in the center and often more pro-
nounced in the gray than in the white matter.
Hemorrhage was already found in acute cases where it
obviously started as perivascular leakage of erythrocytes
leading to ring hemorrhages. In more advanced cases,
the endothelial layer exhibited signs of degeneration. In
chronic cases, revascularization became a prominent
feature, whereas hemorrhage resolved. Four dogs
Table 1. Distribution of intramedullary hemorrhage grades and grades of myelomalacia in respect to the neurologi-
cal grades in 34 dogs with intervertebral disk extrusion.
Myelomalacia
Number of Dogs
Hemorrhage
Number of Dogs
Clinical grade Number of Dogs No Focal ADMM No Scattered ring Coalescing ring Mass
II 1 0 1 0 1 0 0 0
III 3 2 1 0 0 2 1 0
IV 6 3 2 1 0 4 0 2
V 24 4 7 13 3 4 12 5
Total 34 9 11 14 4 10 13 7
A1
A2
A3
B1
B2
B3
C1
C2
C3
Fig 2. Transverse canine spinal cord sections at the level of the center (A) and in a remote segment of an aﬀected (B), and of a control
dog (C), and respective H/E staining of the same areas (A1–C1) (H&E, bar = 1000 lm). Immunohistochemistry for endothelin-1 (ET-1) in
white matter astrocytes (black arrows) reveals increasing ET-1 expression from control dogs (C2) over aﬀected dogs in the center (A2) to
aﬀected dogs in remote segments (B2). Neurons in the center (A3) displayed often no (white arrows) or only mild positive staining (black
arrow) compared to control dogs with the majority of cells being positively labeled (black arrow). Also astrocytes in the gray matter were
positively stained for ET-1 (B3, black arrowhead). (A2,3–C2,3: IHC, bar = 50 lm)
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showed no hemorrhage, 10 dogs revealed scattered ring
hemorrhages (grade 1), 13 dogs diﬀuse spread of ery-
throcytes into the parenchyma (grade 2), and 7 dogs
displayed mass hemorrhages (grade 3) in the center
(Table 1).
The remote segments were histopathologically normal
in 18/34 dogs (Fig 2B1), revealed mild white matter
damage (scattered spheroids or axonal loss) in 10/34
dogs, mild damage in or around the central canal in
5/34 dogs, and in 1 dog all of the gray matter displayed
hemorrhagic necrosis. Besides the latter dog, the major-
ity of cases revealed no intramedullary hemorrhage in
the remote segments. Only 3 dogs showed scattered ring
hemorrhages, and 3 dogs had some hemorrhagic debris
within the central canal.
Assessment of Immunohistochemistry
Endothelin-1 immunoreactivity was observed in both
aﬀected and control dogs (Fig 2). Staining varied in
respect to intensity and number of positive cells per
selected microscopic field. In general, astrocytes of the
white matter revealed the most consistent and strongest
intensity of staining, followed by neurons. In astrocytes,
staining was diﬀusely cytoplasmatic also involving cell
processes (Fig 3B, Fig 2A2–C2). In neurons, staining
was distinct granular in the cytoplasm (Fig 1D, Fig
2A3–C3). Endothelial cells were only rarely mildly or
moderately positive (Fig 3C). Additionally, in areas of
malacia, which generally contained vast numbers of git-
ter cells, many macrophages were strongly labeled with
a granular cytoplasmatic pattern and on cell membranes
(Fig 3D). Ependymal cells were occasionally positively
labeled, and neutrophils were not stained.
A B
C D
Fig 3. Immunohistochemistry for endothelin-1 of canine liver (A) and spinal cord (B–D) tissue. A—Marked immunostaining of bile duct in
liver serving as positive control (IHC, bar = 50 lm); B—Spinal cord white matter with strongly stained astrocytes (arrows) and a small capillary
with positively stained endothelial cells (arrowhead) (IHC, bar = 50 lm); C—Severely necrotic area in the center of the lesion with small vessels
with positively stained endothelial cells (arrows) (IHC, bar = 20 lm); and D—Positively stained macrophages (arrows) (IHC, bar = 20 lm).
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Fig 4. The endothelin-1 immunoreactivity in astrocytes and neurons
was expressed as scores and calculated by summation of the grades of
number and intensity (eg, ET-1 immunoreactivity in astrocytes =
grade “number of positively stained astrocytes” + grade “intensity of
astrocytic staining”). These scores were used for further statistics. *
Only 28 cases with present neurons on cross section are included.
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In the center of 14/34 dogs, the spinal cord was com-
pletely necrotic. Therefore, the closest adjacent section
with adequately preserved tissue (at least 3 visual fields
in the white matter without malacia) was used (Fig
2A1-3). The results of the semiquantitative IHC analysis
regarding number/percentage of positively stained astro-
cytes/neurons and the intensity of staining is presented
in Figure 9 and in Table S1. The final ET-1 immunore-
activity score (after summation of number and intensity
grades) of astrocytes and neurons is shown in Figure 4
and in Table S1.
In negative control slides, staining of neurons,
astrocytes, macrophages, and endothelial cells was
negative.
Astrocytes
*
*
Grade of hemorrhageGrade of hemorrhage
Center Center
Grade of ET-1 immunoreactivity
*
** *
Remote Remote
Grade of hemorrhageGrade of hemorrhage
Neurons
Grade of ET-1 immunoreactivity
*
*
Fig 5. Associations between the endothelin-1 immunoreactivity of astrocytes and neurons at the center and in segments remote from the
center and the degree of hemorrhage. The box represents the 25th, 50th, and 75th percentile of the distribution; the whiskers approximate
the 5th–95th percentile range. (* indicates values of P < .05).
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Statistical Analyses
Association between ET-1 Immunoreactivity and Grade
of Intramedullary Hemorrhage. In astrocytes, ET-1
immunoreactivity was significantly higher in dogs with
hemorrhage than in control dogs both at the level of
IVD extrusion and in segments remote from the IVD
extrusion (both P < .001) (Fig 5).
In neurons, ET-1 immunoreactivity was significantly
lower at the level of IVD extrusion in dogs with no/mini-
mal and moderate hemorrhage than in control dogs
*
*
*
Grade of myelomalacia
Center Center
Astrocytes
Grade of ET-1 immunoreactivity
*
*
Remote Remote
*
Grade of myelomalacia
Grade of myelomalacia
Grade of myelomalacia
Neurons
Grade of ET-1 immunoreactivity
*
*
Fig 6. Associations between the endothelin-1 immunoreactivity of astrocytes and neurons at the center and in segments remote from the
center and the degree of myelomalacia. The box represents the 25th, 50th, and 75th percentile of the distribution; the whiskers approximate
the 5th–95th percentile range. (* indicates values of P < .05)
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(P = .004), but not diﬀerent to the control dogs in seg-
ments remote from the IVD extrusion (P = .355) (Fig 5).
Association between ET-1 Immunoreactivity and
Extension of Myelomalacia. In astrocytes, ET-1
immunoreactivity was significantly higher in aﬀected
dogs both at the level of IVD extrusion and in segments
remote from the IVD extrusion than in control dogs
irrespective of the grade of myelomalacia (P = .001,
P < .001, respectively) (Fig 6).
In neurons, ET-1 immunoreactivity was significantly
lower in dogs with focal myelomalacia and ADMM
than in control dogs at the level of IVD extrusion
(P = .008), but not diﬀerent to the control dogs in seg-
ments remote from the IVD extrusion (P = .161)
(Fig 6).
Longitudinal Distribution of ET-1 in Spinal Cord. In
both astrocytes and neurons, ET-1 immunoreactivity
was significantly lower at the level of IVD extrusion
than in segments remote from the IVD extrusion
(P = .013, P = .001, respectively) (Fig 7).
In controls, ET-1 immunoreactivity was equally dis-
tributed longitudinally.
Association between ET-1 immunoreactivity and dura-
tion of clinical signs. No association was found between
ET-1 immunoreactivity and duration of clinical signs.
Descriptive evaluation of in situ hybridization. Endothe-
lin-1 mRNA was present in nearly all neurons in the
region of the center as well as remote from the center
(Fig 8B–D). However, the intensity of staining was very
variable (also between sections of one case on the same
slide). Additionally, a few endothelial cells were mildly
stained (Fig 8B). Astrocytes, macrophages and neu-
trophils were not stained in ISH.
Also in control dogs, only neurons displayed ET-1
mRNA.
Staining of canine liver tissue with the labeled sense
probe was negative (negative control) and with the
labeled antisense probe positive (positive control)
(Fig 8A).
Discussion
In IVD extrusion in dogs, intramedullary hemorrhage
is a frequent finding, and is associated with longitudinal
extension of myelomalacia.5 The precise pathomecha-
nisms of such ADMM remain uncertain. In view of the
proposed involvement of increased ET-1 expression in
experimental SCI in small rodents17,18 and the known
stimulating eﬀect of blood products, in particular oxy-
hemoglobin, on ET-1 production,25 we evaluated both
mRNA and peptide immunoreactivity of ET-1 in intact
and injured canine spinal cord after IVD extrusion
using ISH and IHC.
The aim of this study was to investigate whether ET-
1 immunoreactivity is enhanced in the spinal cord after
IVD extrusion, and if so, whether this could be posi-
tively associated with intramedullary hemorrhage and
tissue destruction.
Endothelin-1 was expressed by astrocytes, macro-
phages and neurons and only rarely by endothelial cells
in all dogs. In astrocytes at the center, ET-1 immunore-
activity was significantly higher in aﬀected dogs than in
control dogs irrespective of the grade of hemorrhage or
myelomalacia. ET-1 immunoreactivity in neurons at the
center was lower than in control dogs. In both astro-
cytes and neurons, there was a higher ET-1 immunore-
activity in spinal cord regions remote from the center
than in the center itself. ET-1 mRNA was present in
nearly all neurons with variable intensity, but not in
astrocytes. As described in the normal human spinal
cord,34 we could detect mRNA as well as peptide
expression of ET-1 in various cell types both in intact
and injured spinal cord of dogs. However, in line with
the literature, ISH was usually not congruent with IHC.
In contrast to the strong mRNA immunoreactivity in
nearly all neurons (Fig 8B–D), ET-1 IHC was positive
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Fig 7. Comparison between the endothelin-1 immunoreactivity in
the center to the immunoreactivity in segments remote from the
center. The endothelin-1 immunoreactivity of astrocytes and neu-
rons is significantly higher remote from the center (P = .013,
P = .001, respectively). The box represents the 25th, 50th, and
75th percentile of the distribution; the whiskers approximate the
5th–95th percentile range.
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in only one-third of the aﬀected animals at the site of
IVD extrusion and in 75% of control animals (Fig
2A3–C3, Fig 9). Also in humans, only 20% of neurons
in normal spinal cord were weakly stained for the
peptide.34
In reverse, astrocytes were consistently immunos-
tained for ET-1 (Fig 2A2–C2), but we could not detect
mRNA in these cells in our dogs including 11 chronic
cases with active gliosis (Fig 8C). This is at variance
with the findings in a murine model where ET-1 mRNA
was detected in astrocytes in the process of active glio-
sis,24,35 and binding of the peptide ET-1 to ETB recep-
tor in astrocytes lead to their activation.35 On the other
hand, in rats, it has been shown that there is no simul-
taneous ET-1 mRNA elevation when the ET-1 peptide
in astrocytes is increased,36 and that increased ET-1
immunoreactivity in astrocytes and endothelial cells
occurs even though the mRNA level before and after
SCI remained constant.27,37 It is postulated that ET-1
production in rat astrocytes is mainly post-transcrip-
tionally regulated in response to thrombin stimulation.36
In view of the inherent instability of mRNA it is clear
that the vagaries of ISH are also caused by technical
factors such as autolysis, fixation, embedding and stor-
age. Therefore, we refrained from evaluating ISH stain-
ing intensity and focused only on its cellular and
anatomical localization. Reliable quantitative assess-
ment would require fresh material taken at predeter-
mined intervals, which would be diﬃcult in clinical
cases.
We also found marked ET-1 immunoreactivity in
macrophages which is consistent with the finding that
human macrophages synthesize and secrete ET-1,38,39
but in contrast to human neutrophils which are able to
express mRNA of ET-1 and release the mature pep-
tide40 we could not detect ET-1 in canine neutrophils.
Comparing injured to normal spinal cord of control
dogs, we detected a significantly lower ET-1 immunore-
activity in neurons in the center (Fig 4). Since the gray
matter is the initial site of spinal cord damage after
mechanical impact and compression, we assume that
the decreased ET-1 immunoreactivity in neurons follows
the primary injury of these cells which are highly sensi-
tive to ischemia.
In contrast, we found a significantly higher expres-
sion of ET-1 in astrocytes of the white matter in the
region of the IVD extrusion (Fig 2A2) than in normal
spinal cord of control dogs (Fig 2C2). This is consis-
tent with the observations in experimental SCI in
small rodents.37 Additionally, a significant upregula-
tion in both the immunoexpression and number of
astrocytes expressing ETB receptors occurs after exper-
imental SCI in rats, whereas the vascular expression
of the ETA and ETB receptors remained unchanged,
16
because blocking of ETB receptors inhibited astrocytic
growth after SCI in rats,37 we conclude that ET-1 has
probably an eﬀect on astrocytic proliferation in canine
SCI. While it is still unclear if reactive astrogliosis is
beneficial or detrimental to neuronal survival and
regeneration after SCI, there is evidence to suggest
that ET’s action on reactive glial cells might promote
neurotoxicity.16,22,41
Since dogs with IVD extrusion revealed diﬀerent
grades of intramedullary hemorrhage in the center, we
A B
C D
Fig 8. In situ hybridization for endothelin-1 of canine liver (A) and spinal cord (B–D) tissue. A—Bile duct of the liver serving as positive
control (ISH, bar = 20 lm); B—Spinal cord gray matter with strongly stained neuron (arrowhead) and a small capillary with mildly posi-
tively stained endothelial cells (arrow) (ISH, bar = 50 lm); C—Ventral horn of the spinal cord of an aﬀected dog with multiple neurons.
Astrocytes in the adjacent white matter (asterisk) were not stained (ISH, bar = 100 lm); D—Positively stained neuron in larger magnifica-
tion (ISH, bar = 20 lm).
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could assume in analogy to in vitro models that the ini-
tial ET-1 upregulation resulted from the presence of
oxyhemoglobin in the lesion.25 Indeed, we found a posi-
tive association between occurrence of hemorrhage and
immunoreactivity of ET-1 in astrocytes. However,
upregulation of ET-1 in canine IVD disease occurred
early after the initial insult and appeared to be sus-
tained over several weeks since we could not detect sig-
nificant diﬀerences between the 3 (acute, subacute,
chronic) groups, therefore, besides hemorrhage in the
acute stage of the disease other mechanisms are proba-
bly involved in continuing expression of ET-1 in SCI.
There was marked upregulation of ET-1 immunoreac-
tivity in astrocytes in spinal cord segments distant from
the center (Fig 2B2) which to our knowledge has not
been reported in the rodent models of SCI. One possi-
ble explanation for this phenomenon could be that ET-
1 can act in an autocrine and paracrine way24,42,
thereby activating ET-1 expression in neighboring astro-
cytes in this way spreading expression to distant areas.
Also, in view of the already mentioned fact that blood
products are powerful inducers of ET-1, another possi-
ble route of spreading ET-1 is hemorrhagic cord debris
including macrophages frequently extending rostrally
and caudally from the initial injury site through the
central canal and subdural space.5
Even though we found an association between longi-
tudinal extension of myelomalacia and ET-1 immunore-
activity (Fig 6), a causal association between ET-1
upregulation in astrocytes and progression of cord dam-
age remains to be proven. While the literature on SCI
generally emphasizes the detrimental eﬀects of ET-1
excess, this compound could also have beneficial eﬀects.
For example, ET-1 stimulates the formation of heme
oxygenase-1 whose products (bile pigments) have
antioxidative eﬀects to protect the central nervous sys-
tem against free radicals.8 Endothelin-1 exerts direct
angiogenic activities on endothelial cells by promoting
proliferation and migration of endothelial cells. In addi-
tion, ET-1 has indirect angiogenic activities by inducing
vascular endothelial growth factor production by
endothelial cells and vascular smooth muscle cells.38,42–44
Assuming that negative eﬀects prevail, ET-1 upregu-
lation could be directly involved in the progression of
myelomalacia because of its potent vasoconstrictive
eﬀects after binding to ETB1 receptors in smooth muscle
cells of arterioles resulting in ischemia-induced cell
death,19 or because ET-1 induces release of neurotoxic
molecules like glutamate resulting in neuronal cell
death.45,46 Additionally, damage might be inflicted
because of the involvement of ET-1 in BSCB break-
down,12,17 activation of nociceptive neurons,47 and
induction of several inflammatory mediators in neu-
trophils and macrophages.38,40
Our observation of enhanced ET-1 immunoreactivity
spreading over multiple spinal cord segments could help
to explain the pathogenesis of ADMM. However, we
did not detect a linear correlation between ET-1
immunoreactivity and severity of spinal cord damage.
While this point requires further studies with more
eﬀective quantitative techniques and larger case
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Fig 9. Upper Part—Number of endothelin-1 positively stained
astrocytes in 3 randomized visual fields and the intensity of staining
expressed in grades 1–4, respectively, and the resulting distribution
of grades in the center and remote segments of the spinal cord in
aﬀected and in control dogs. Lower Part—Percentage of endothe-
lin-1 positively stained neurons per transverse section of the spinal
cord expressed in grades 1–3, the intensity of staining expressed in
grades 1–4, and the resulting distribution of grades in the center
and remote segments in aﬀected and in control dogs.
* Only 28 cases with present neurons on cross-section are included.
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numbers, it is very likely that additional multiple factors
are involved in longitudinal spreading of myelomalacia
after IVD extrusion. Nevertheless, it might be worth-
while to further explore therapeutic options targeting
ET-1 expression like ET receptor antagonists and
endothelin converting-enzyme inhibitors to reduce the
ET-1-induced ischemia and astrogliosis, and to increase
neuronal survival, regeneration and function.48–50
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